Clinical Trials Logo

Clinical Trial Summary

In case of insufficient oxygen supply to the brain of a newborn child (perinatal asphyxia), toxic compounds will be formed. These toxic compounds will damage the cells of the brain. 2 Iminobiotin (2 IB) is an investigational medicinal product that is related to vitamin B7. From studies in animals it has been shown that 2-IB may prevent the formation of the toxic compounds. Also it has been shown to be safe in in studies in juvenile animals and in healthy, adult male volunteers. The doctors hope that this will prevent (part of) the potential brain damage that may result from lack of oxygen to the brain.

This study is the first study in the target population: newborn with moderate to severe oxygen shortage during birth. In this study the investigators evaluate short term efficacy, safety and pharmacokinetics of 2-Iminobiotin. In the follow-up phase the investigators evaluate the long term efficacy and safety.

The study hypothesis is that 2-Iminobiotin will help to decrease the brain damage after oxygen shortage and is indeed safe. The brain damage will be measured both in the first week and during the first two years of life. The study was designed as a study with two parts an open label pilot part (6 patients) and a double-blind randomised part (60 patients). Due to lack of recruitment it was decided in September2014 to stop recruitment after the open label pilot part of the study (6 patients).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01626924
Study type Interventional
Source Neurophyxia B.V.
Contact
Status Terminated
Phase Phase 2
Start date June 2012
Completion date March 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06322732 - Optimization of Routine Obstetric and Neonatal Care in the Management of Severe Perinatal Asphyxia in Term or Near-term Newborns: Analysis of Sub-optimal Care
Completed NCT05687708 - Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia N/A
Completed NCT00062452 - Esophageal Motility and Airway Defenses Among Infants N/A
Completed NCT05946681 - Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings
Completed NCT02002039 - Neuroprotective Role of Erythropoietin in Perinatal Asphyxia Phase 2/Phase 3
Completed NCT04820504 - Augmented Infant Resuscitator to Enhance Newborn Ventilation N/A
Completed NCT02071160 - Melatonin for Neuroprotection Following Perinatal Asphyxia Phase 1/Phase 2
Recruiting NCT06090968 - Umbilical Cord Milking Versus Immediate Cord Clamping in Full Term Neonates (≥ 37 Weeks) Requiring Resuscitation N/A
Completed NCT03854435 - Determination of Heart Rate in Infants Needing Resuscitation at Birth N/A
Completed NCT02700854 - Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2 Phase 1
Active, not recruiting NCT05349175 - Augmented Infant Resuscitator (AIR): Transitioning a Novel Behavior Change Innovation to Drive Newborn Ventilation Skills Enhancement N/A
Completed NCT03968861 - Outcome After 24 Months of Participants in the TOBY Xenon Study
Recruiting NCT05574855 - Evaluation of Haemodynamic in Neonates Treated With Hypothermia"
Completed NCT00624871 - Ascorbic Acid and Ibuprofen in Infants With Hypoxic Ischemic Encephalopathy N/A